HDA UK Media And Political Bulletin – 27 April 2017

New Government ‘must be more ambitious in securing a world-class NHS’, says UK pharmaceutical industry

ABPI, 27 April 2017

 

The Association of the British Pharmaceutical Industry (ABPI) published its manifesto for the 2017 UK General Elections this morning calling on the Government to be more ambitious in securing a world-class NHS for patients and improve access to medicines in line with other developed nations. Launched at the ABPI’s Annual Conference in London, this manifesto sets out the industry’s three priorities to improve the use of medicines and grow the UK’s status as a global hub for life sciences and pharmaceuticals including 1. Securing a world-class NHS for patients 2. Securing global investments and jobs and 3. Securing a new relationship with the European Union (EU) that prioritises patients and public health.

 

Parliamentary Coverage

Health Service Medical Supplies (Costs) Bill 2016-17

House of Lords, 26 April 2017

 

Consideration of a Commons amendment to the Bill took place in the House of Lords on 26 April. Both Houses agreed on the text of the Bill which now waits for the final stage of Royal Assent when the Bill will become an Act of Parliament. Royal Assent is scheduled for 27 April.

 

Full Coverage

New Government ‘must be more ambitious in securing a world-class NHS’, says UK pharmaceutical industry

ABPI, 27 April 2017

 

The new Government must be more ambitious in securing a world-class NHS for patients and improve access to medicines in line with other developed nations.

 

Launching its manifesto ​for the 2017 UK General Election, the Association of the British Pharmaceutical Industry (ABPI) is calling on the Government elected on June 8th to set out a clear strategy to make NHS patient outcomes the best in the world. This should start by:

 

Increasing healthcare investment in line with the G7 average of 11.3% of Gross Domestic Product (GDP): the UK is currently sixth lowest out of the G7 nations for investment in healthcare, spending 9.9% of GDP. Only Italy invests less.

 

Improving access to medicines, ensuring that the UK is in the top quartile of OECD countries for patient access to new medicines and vaccines by 2022: UK patient access to medicines is poor in comparison to similar nations; in the first year of launch, patients in France and Germany are around five times more likely to receive a new medicine than patients in the UK.

Lisa Anson, new ABPI President (taking over the post on Thursday 27 April) and Country President of AstraZeneca UK, said:

 

“This General Election comes at a critical juncture. Do we want to improve NHS patient outcomes and ensure Britain continues to be a global player in Life Sciences, or run the risk of the UK becoming a desert for healthcare innovation? Patients and voters will expect each party to set out a clear strategy to address this important issue.

 

“The new Government should commit to bringing healthcare investment in line with the G7 average in order to deliver the services and outcomes that British patients deserve. Ensuring that the NHS and Life Sciences industry are at the heart of the new industrial strategy, and Brexit negotiations, is also crucial for securing this ambition.”

 

The manifesto – ‘Securing the Opportunity for UK Life Sciences by 2022’​ – launched today [27 April] at the ABPI Annual Conference in London – sets out the industry’s three priorities to improve the use of medicines and grow the UK’s status as a global hub for life sciences and pharmaceuticals.

 

1. Securing a world-class NHS for patients

 

The ABPI is asking the next Government to commit to improving patient outcomes fairly and consistently throughout the UK, by:

 

Agreeing a new long term, voluntary Pharmaceutical Price Regulation Scheme (PPRS) in partnership with the pharmaceutical industry that ensures patients in Wales, England, Scotland and Northern Ireland receive medicines at the same levels as the best countries in Europe

 

Balancing the need to maintain a strong pharmaceutical industry by rewarding innovation with the need to secure the best value for money for the NHS

Creating a streamlined, National Institute for Health and Care Excellence (NICE)-led, system for the assessment of medicines in England, integrated into a new, voluntary PPRS, which reduces bureaucracy

 

Measuring NHS patient outcomes through a new, independent assessment

2. Securing global investment and jobs

 

The ABPI is asking the next Government to implement a new industrial strategy that cements the UK’s position as a leading global hub for life science, and attract significant new international investment, by:

 

Reaching a target of 3% of GDP spend on research and development by 2022 through a strategic vision for publicly funded science research

 

Attracting global scientists to the UK and enable the UK to collaborate at scale in global scientific projects

 

Improving the global competitiveness of UK medicines manufacturing, through targeted infrastructure investment in advanced manufacturing

 

Ensuring the NHS is seen as a global early adopter of new cost effective medicines and vaccines

3. Securing a new relationship with the European Union (EU) that prioritises patients and public health

 

The ABPI is asking the next Government to negotiate a new relationship with the EU through a phased transition that secures patient access to medicines and protects public health.

 

Mike Thomspon, ABPI Chief Executive, said:

 

“As we leave the EU, the new Government’s agenda will need to set out the UK’s stall in the global marketplace.

 

“This manifesto lays out the pharmaceutical industry’s vision for an NHS that embraces innovation as the route to greater productivity and sustainability, as well as healthier lives for us all. Alongside targeted investments in our science base and making the right choices in Brexit negotiations, we can cement the UK’s position as a leading global hub for our industry.”​

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?